**LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis**

**Elena García-Martín**, Oswaldo Lorenzo-Betancor, Carmen Martínez, Pau Pastor, Julián Benito-León, Jorge Millán-Pascual, Patricia Calleja, María Díaz-Sánchez, Diana Pisa, Laura Turpín-Fenoll, Hortensia Alonso-Navarro, Lucía Ayuso-Peralta, Dolores Torrecillas, Elena Lorenzo, José Francisco Plaza-Nieto, José A G Agúndez and Félix Javier Jiménez-Jiménez

### Abstract

**Background:** Some recent experimental data suggest a possible role of LINGO-1 in the pathogenesis of multiple sclerosis (MS). In an attempt to identify genetic biomarkers related to MS susceptibility, we genotyped two common SNPs in the *LINGO1* gene which have been associated to other neurological conditions, in patients with MS and in healthy subjects. These SNPs are linked to several SNPs within the *LINGO1* gene, especially in individuals of Oriental or Caucasian descent.

**Methods:** We analyzed the allelic and genotype frequency of two *LINGO1* variants (rs9652490 and rs11856808) in 293 patients with MS and 318 healthy controls, using KASPar assays.

**Results:** *LINGO1* rs9652490 and rs11856808 allelic and genotype frequencies did not differ significantly between MS patients and controls. The minor allele frequencies for rs9652490 were 0.171 (95% CI = 0.140-0.201) and 0.167 (95% CI = 0.138-0.196) for cases and controls, respectively (p = 0.853). For rs11856808 the minor allele frequencies were 0.317 (95% CI = 0.280-0.355) and 0.310 (95% CI = 0.274-0.346) for cases and controls, respectively (p = 0.773). Allele and genotype frequencies were unrelated with the age of onset of MS, gender, and clinical course of MS. In addition, haplotype analyses did not reveal any putative risk related to haplotypes.

**Conclusions:** These results suggest that *LINGO1* rs9652490 and rs11856808 polymorphisms are not related with risk for MS. This study adds to other published evidence indicating that, to date, the *LINGO1* SNPs studied here could be useful risk biomarkers of developing essential tremor, but not other movement disorders.

**Keywords:** Multiple sclerosis, Genetics, Genetic polymorphisms, LINGO-1, Risk factors

---

**Background**

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder with axonal degeneration affecting the Central Nervous system, which shows three major evolutive phenotypes: relapsing-remitting, primary progressive and secondary progressive. The etiology of MS is unknown, but it is probably multifactorial, with an interplay of genetic, ethnic, geographical and environmental factors (infectious or chemical) [1-5]. It has been proposed that MS is an autoimmune disorder with susceptibility influenced, if not determined, by a relatively small number of genes [1]. Findings from studies on seasonality in MS patients’ birth, disease onset and exacerbations, as well as apparent temporal trends in incidence and gender ratio support an influential effect of viruses, metabolic and lifestyle factors on MS risk. Epstein-Barr virus, vitamin D status, and smoking are factors that may explain such epidemiological patterns [4].

A haplotype within the major histocompatibility region is the major risk factor for MS. But despite clear evidence for a genetic component additional risk, specific gene variants were not identified until the recent advent...
of genome-wide association studies (GWAS). Until 2010, 11 GWAS have been conducted on MS, and, together with follow-up studies, these GWAS have confirmed 16 loci with genome-wide significance [6,7]. Many of these common risk variants are located at, or near to, genes with central immunological functions (such as interleukin 2 and 7 receptors, CD58, CD6, CD40, TNFRSF1A and others) and the majority are associated with other autoimmune diseases [6,7]. A further report of the International Multiple Sclerosis Genetics Consortium identified at least 50 loci related with the risk for MS [8].

Although the underlying molecular mechanisms for the axonal degeneration are unknown, the degree of inflammatory demyelination correlates with the extent of axonal damage. This suggests an involvement of the proinflammatory mediators in inducing axonal degeneration [9]. However, the alternative possibility that axonal regeneration should be severely impaired in MS lesions could be suggested, since an accumulation of glial scar and neurite growth inhibitors provide a non-permissive environment for re-growth of damaged axons [10].

LINGO1 (leucine rich repeat and Ig domain containing Nogo receptor interacting protein-1) has a possible role in the pathogenesis of MS. LINGO1 is a transmembrane protein expressed in neural cells which inhibits the differentiation of oligodendrocyte precursor cells into mature oligodendrocytes, as well as myelination and remyelination [11,12]. LINGO1 comprises 12 leucine rich repeats followed by an immunoglobulin (Ig) domain and a short cytoplasmic tail. It is encoded by the LINGO1 gene (OMIM 609791, Gene Identity 84894) located in the chromosome 15q24.3 [13,14]. In neurons, LINGO1 simultaneously interacts with the Nogo-66 receptor (NgR) and p75NTR or TROY to form a receptor complex that binds the structurally diverse associated glycoprotein and oligodendrocyte myelin glycoprotein, resulting in the restriction of axonal elongation via activation of the small GTPase RhoA [14-16]. Two LINGO1 variants designated as rs9652490 and rs11856808 have been claimed to be associated in case–control GWAS with other neurological conditions such as essential tremor [17,18] and Parkinson’s disease [18,19]. Further studies confirmed the association with essential tremor, but discarded a major association with Parkinson’s disease [20–24]. These single nucleotide polymorphisms (SNPs) are, according to HapMap, tag-SNPs for the following SNPs located within the LINGO1 gene: rs907400, rs8029432, rs18777294, rs7165679, rs9920101 and rs9920127, as well as nine additional SNPs in the 3’ flanking region of the gene. Figure 1 shows that the linkage between the two SNPs analyzed in this study and the six SNPs located within the gene differ, depending on ethnicity.

In an attempt to identify additional factors involved in MS susceptibility, we genotyped the SNPs rs9652490 and rs11856808 in the LINGO1 gene, in patients with MS and in healthy subjects. Although LINGO1 polymorphisms were not significantly associated with the risk and hence are not mentioned among the possible susceptibility genes in GWAS studies, the possible role of LINGO1 in the pathogenesis of MS suggests that the LINGO1 gene should be a candidate gene for modifying MS risk.

Methods

Patients and controls

We recruited 293 unrelated Caucasian Spanish patients who fulfilled McDonald’s criteria for definite MS [25], with no other previous neurological diseases. Recruiting sources were the following: the “Multiple Sclerosis Association of Madrid”; n = 165 cases), the Health Areas of the Hospital La-Mancha-Centro (Alcázar de San Juan, Ciudad Real; n = 65 cases), and University Hospitals “Doce de Octubre” (Madrid, n = 32 cases), and “Príncipe de Asturias” (Alcalá de Henares, Madrid; n = 31 cases). The control group was composed of 318 healthy unrelated Caucasian Spanish individuals gender and age-matched with the patients (97 men, 221 women; mean age 43.76 ± 12.4 years). These patients participated in previous genetic studies [26–28]. The control individuals were students or professors from the University of Extremadura, Badajoz, Spain (n = 150), and the healthy spouses of patients with neurological disorders who came from different regions of Spain to the Department of Neurology, Clínica Universitaria de Navarra, University of Navarra School of Medicine, Pamplona, Spain (n = 168). All the participants were included in the study after giving written informed consent. Table 1 summarizes the characteristics of the individuals included in the study. The protocol was approved by the Ethics Committees of the University Hospitals “Príncipe de Asturias” and “Infanta Cristina” (Badajoz) and collaborating centres. The study was conducted according to the principles expressed in the declaration of Helsinki.

Genotyping of LINGO1 rs9652490 and rs18856808 polymorphisms

Genomic DNA was obtained from peripheral leukocytes and purified according to standard procedures. Two polymorphisms of LINGO1 gene, rs9652490 A/G and rs11856808 C/T, were genotyped using KASPar assays according to the manufacturer’s protocol (www.kbioscience.co.uk). PCR was performed on a 96-well Tetrad 2 Peltier Thermal Cycler (BIO-RAD, Hercules, CA). PCR KASPar’s protocol was performed as following: a denaturation step of 10 min, twenty–eight cycles of 15 sec denaturing at 94°C, annealing of 20 sec at 57°C, and extension of 30 sec at 72°C. PCR were followed by a final extension step of 5 min at 72°C. Genotype calling was performed in an allelic discrimination analysis module of the 7300
Figure 1 (See legend on next page.)
The statistical power was calculated for the sample size of 303 patients following the standard color scheme (D/LOD), and the D' values (x100) are shown when relevant. Top: The area covers the whole LINGO1 gene as well as the 3' flanking region. The SNPs tested are marked at the right side of the figure. These data correspond to Caucasian individuals (Utah residents with ancestry from northern and western Europe). Bottom: Linkage figures focusing on the two SNPs tested and six SNPs located within the LINGO1 gene. The populations correspond to: CEU, Utah residents with ancestry from northern and western Europe; ASW, African ancestry in Southwest USA; JPT, Japanese in Tokyo, Japan; CHB, Han Chinese in Beijing, China; MXL, Mexican ancestry in Los Angeles, California; TSI, Tuscany in Italy. (see the website http://www.sanger.ac.uk/resources/downloads/human/hapmap3.html).
Table 2 LINGO1 genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers

|                  | MS PATIENTS (N = 293, 586 ALLELES) | CONTROLS (N = 318, 636 ALLELES) | Intergroup comparison values | MS WOMEN (N = 203, 406 ALLELES) | CONTROL WOMEN (N = 221, 442 ALLELES) | Intergroup comparison values | MS MEN (N = 90, 180 ALLELES) | CONTROL MEN (N = 97, 194 ALLELES) | Intergroup comparison values |
|------------------|-----------------------------------|---------------------------------|-------------------------------|-------------------------------|------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| rs9652490 GENOTYPE |                                   |                                 |                               |                               |                                    |                               |                               |                               |                               |
| A/A              | 197 (67.2%)                       | 222 (69.8%)                     | P = 0.197                     | 139 (68.5%)                   | 153 (69.2%)                        | P = 0.170                     | 58 (64.4%)                    | 69 (71.1%)                    | P = 0.651 *                  |
| A/G              | 92 (31.4%)                        | 86 (27.0%)                      |                               | 62 (30.9%)                    | 60 (27.1%)                         | P = 0.170                     | 30 (33.3%)                    | 26 (26.8%)                    |                               |
| G/G              | 4 (1.4%)                          | 10 (3.1%)                       |                               | 2 (1.0%)                      | 8 (3.6%)                           |                               | 2 (2.2%)                      | 2 (2.1%)                      |                               |
| Allele A         | 486 (82.9%)                       | 530 (83.3%)                     |                               | 340 (83.7%)                   | 366 (82.8%)                        |                               | 146 (81.1%)                   | 164 (84.5%)                   |                               |
| Allele G         | 100 (17.1%)                       | 106 (16.7%)                     | OR (95% CI) = 1.03 (0.76-1.39)| 66 (16.3%)                    | 76 (17.2%)                         | OR (95% CI) = 0.94 (0.65-1.34)| 34 (18.9%)                    | 30 (15.5%)                    | OR (95% CI) = 1.27 (0.74-2.18)|
|                  |                                   |                                 |                               |                               |                                    |                               |                               |                               |                               |
| rs11856808 GENOTYPE |                                   |                                 |                               |                               |                                    |                               |                               |                               |                               |
| C/C              | 137 (46.8%)                       | 145 (45.6%)                     |                               | 95 (46.8%)                    | 101 (45.7%)                        |                               | 42 (46.7%)                    | 44 (45.4%)                    |                               |
| C/T              | 126 (43.0%)                       | 149 (46.9%)                     | P = 0.407                     | 90 (44.3%)                    | 103 (46.6%)                        | P = 0.852                     | 36 (40.0%)                    | 46 (47.4%)                    | P = 0.313                     |
| T/T              | 30 (10.2%)                        | 24 (7.5%)                       |                               | 18 (8.9%)                     | 17 (7.7%)                          |                               | 12 (13.3%)                    | 7 (7.2%)                      |                               |
| Allele C         | 400 (68.3%)                       | 439 (69.0%)                     |                               | 280 (69.0%)                   | 305 (69.0%)                        |                               | 120 (66.7%)                   | 134 (69.1%)                   |                               |
| Allele T         | 186 (31.7%)                       | 197 (31.0%)                     | OR (95% CI) = 1.04 (0.81-1.32)| 126 (31.0%)                   | 137 (31.0%)                        | OR (95% CI) = 1.00 (0.75-1.34)| 60 (33.3%)                    | 60 (30.9%)                    | OR (95% CI) = 1.08 (0.60-1.43)|
|                  |                                   |                                 |                               |                               |                                    |                               |                               |                               |                               |

P values correspond to 3x2 contingency tables (exact test). * Fisher's exact test.
AC (63.5% among patients and 69.2% among control individuals), followed by GT (19.4% and 16.6%, respectively) and AT (15.2% and 14.2%, respectively). These analyses did not reveal any differences in haplotype frequencies on comparing patients and control individuals (p > 0.05 for all comparisons). Haplotypes did not differ when subgroups of patients were compared according to gender, age at onset, MS phenotypes or severity scores (p > 0.05 for all comparisons).

Discussion

The possible role of LINGO1 in the pathogenesis of MS makes it reasonable to analyse the possible relationship between LINGO1 polymorphisms and the risk of MS. In the present study, we found no significant differences in allele frequencies or haplotype frequencies for the rs9652490 and rs11856808 polymorphisms when comparing patients with MS and healthy control subjects. Nor were these polymorphisms related with the age at onset of MS or with the evolutive type of MS. The findings obtained, though negative, are novel and represent an incremental advance in the knowledge of the clinical implications of the LINGO1 gene polymorphism.

Some experimental data suggest a possible role of LINGO1 in the pathogenesis of MS: (a) Nogo-A expression has been found to be enhanced in surviving oligodendrocytes, while NgR has been found to be up-regulated in reactive astrocytes and macrophages/microglia in chronic active demyelinating lesions of MS [33], (b) TROY has been found to be up-regulated, whereas LINGO1 expression has been found to be reduced, in MS brains [34], (c) LINGO1 knockout mice have shown earlier onset of myelination of CNS axons than the wild-type, and greater resistance to the development of myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) [35]; (d) Treatment with antibody antagonists against LINGO1 function induces functional recovery and increases integrity of axons in MOG-induced EAE [35], and promotes oligodendrocyte precursor cell differentiation and remyelination in different experimental models of demyelination and remyelination [36].

The LINGO1 SNPs analyzed in this study have been studied as putative risk biomarkers for other movement disorders. A recent meta-analysis, which included 3,972 essential tremor (ET) patients and 20,714 controls for the LINGO1 rs9652490 polymorphism, and 2,076 ET patients and 18,792 controls for the rs11856808 polymorphism, concluded that the rs11856808 polymorphism was related with increased risk for both total and familial ET, whereas the rs9652490 polymorphism was related with increased risk for familial ET [21]. With regard to Parkinson’s disease, another recent meta-analysis including 5,541 patients and 5,647 controls for

| Table 3 | LINGO1 genotypes and allelic variants in patients with MS, and relation with the evolutive type of MS |
|---------|--------------------------------------------------------------------------------------------------|
| RELAPSING-REMITTING MS (N = 159; 318 ALLELES) | INTERGROUP COMPARISON VALUES | SECONDARY PROGRESSIVE MS (N = 91; 182 ALLELES) | PRIMARY PROGRESSIVE MS (N = 43; 86 ALLELES) | CONTROLS (N = 318, 636 ALLELES) |
| rs9652490 | GENOTYPE | | | |
| A/A | 102 (64.2%) | 62 (68.1%) | 33 (76.7%) | 222 (69.8%) |
| A/G | 56 (35.2%) | P = 0.055 | 26 (28.6%) | P = 0.956 | 10 (23.3%) | P = 0.405 | 86 (27.0%) |
| G/G | 1 (0.6%) | 3 (3.3%) | 0 (0.0%) | 10 (3.1%) |
| Allele A | 260 (81.8%) | – | 150 (82.4%) | – | 76 (88.4%) | – | 530 (83.3%) |
| Allele G | 58 (18.2%) | OR (95% CI) | 32 (17.6%) | OR (95% CI) | 10 (11.6%) | OR (95% CI) | 106 (16.7%) |
| rs11856808 | GENOTYPE | | | |
| C/C | 67 (42.1%) | 43 (47.3%) | 27 (62.8%) | 145 (45.6%) |
| C/T | 77 (48.4%) | P = 0.670 | 35 (38.5%) | P = 0.095 | 14 (32.6%) | P = 0.112 | 149 (46.9%) |
| T/T | 15 (9.4%) | 13 (14.3%) | 2 (4.7%) | 24 (7.5%) |
| Allele C | 211 (66.4%) | – | 121 (66.5%) | – | 68 (79.1%) | – | 439 (69.0%) |
| Allele T | 107 (33.6%) | OR (95% CI) | 61 (33.5%) | OR (95% CI) | 18 (20.9%) | OR (95% CI) | 197 (31.0%) |
| | 1.13 (0.85-1.51) | 1.12 (0.79-1.60) | 0.59 (0.34-1.02) | **P = 0.040** | **P = 0.515** | **P = 0.056** |

P values correspond to 3x2 contingency tables (exact test).
the rs9652490 polymorphism and 3,276 patients and 3,371 controls for the rs11856808 polymorphism concluded that these polymorphisms could not be considered as major risk factors for susceptibility to PD [22].

Several SNPs have been described within the LIN101 gene and in the 3′ flanking region (Figure 1). It is to be noted that most genetic association studies on LIN101 focused on the same SNPs which were analyzed in the present study [17-19,21-24,37-50]. Although several LIN101 nonsynonymous SNPs have been described, namely rs113329801, rs201732477, rs112205560, rs150289554, rs113096707, rs188738703, rs200688402, rs200463885, rs9855, rs201517725, rs184237450, rs77436810, rs193100227, rs111741384, rs202233236, rs199976207, rs199628078, rs201438433, rs140914739, rs200528664, rs111605415 and rs202223502, none of these SNPs show a minor allele frequency over 0.0005 (see the website http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?showRare=on&chooseRs=all&go=Go&locusId=84894). Therefore, the identification of one heterozygous individual out of 1000 individuals studied is to be expected. This precluded the analysis of these nonsynonymous SNPs as putative risk factors. Nevertheless, the two SNPs studied are linked with other SNPs within the coding region of the LIN101 gene. Figure 1 show that linkage varies depending on the population studied, being low in individuals of African descent, high in individuals of Oriental descent or in related populations (of American descent), and intermediate in individuals of Caucasian descent. The Italian Tuscany population shows a higher linkage than other Caucasian individuals, probably due to genetic admixture with other Mediterranean populations. This admixture took also place in Spain. The Figure indicates that the two SNPs analyzed in this study are linked to the rest of the SNPs shown in the Figure.

The present study has some limitations. First, the size of analyzed cohorts may not be sufficient for strict conclusions about LIN101 role in MS. As was shown in a previous publication about the role of LIN101 in essential tremor risk, individual studies of small number of patients gave very contradictory results [21]. Second, although the sample size is adequate to detect an OR as small as 1.5, a more modest association would not be detected. Third, because EDSS or progression index are not completely adequate measures of disease severity, the negative association observed in this study does not rule out a putative association with disease severity. Moreover, because the cohort study included MS patients with different degrees of severity, it is not adequate for the investigation of the influence of LIN101 genotypes on the disability or severity of MS (the ideal study for this purpose should include genotyping of patients with a recent diagnosis of MS with similar follow-up periods).

Conclusions
In summary, taking in account the limitations of the present study, our results suggest that rs9652490 and rs11856808 genotype and allelic variants are not related with the risk for MS in Caucasian Spanish people.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
EGM participated in the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, administrative, technical, and material support, supervision, and obtaining funding. OLB participated in acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, administrative, technical, and material support. CM participated in acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, administrative, technical, and material support. PP participated in the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, administrative, technical, and material support, supervision, and obtaining funding. JBL participated in acquisition of data, and critical revision of the manuscript. JM participated in acquisition of data, and critical revision of the manuscript. PC participated in acquisition of data, and critical revision of the manuscript. MDS participated in acquisition of data, and critical revision of the manuscript. DP participated in acquisition of data, and critical revision of the manuscript. LTJF participated in acquisition of data, and critical revision of the manuscript. JN participated in acquisition of data, analysis and interpretation of data, critical revision of the manuscript, administrative, technical, and material support. LAP participated in acquisition of data, and critical revision of the manuscript. DJ participated in acquisition of data, and critical revision of the manuscript. EL participated in acquisition of data, and critical revision of the manuscript. JF participlated in acquisition of data, and critical revision of the manuscript. JAPA participated in conception and design of the study, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, administrative, technical, and material support, and supervision. All authors read and approved the final manuscript.

Acknowledgments
We are grateful to Gara Esguevillas for technical assistance and to Professor James McCue for assistance in language editing. This work was supported in part by grants PS09/00943, PS09/00469, PI12/00241, PI12/00324 and RETICS RD12/0013/0002 from Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain, SAF2006-10126 and SAF2010-2229-C02-01 from the Spanish Ministry of Science and Innovation and GRI0068 from Junta de Extremadura, Spain. Financed in part with FEDER funds from the European Union.

Author details
1Department of Biochemistry and Molecular Biology, University of Extremadura, Cáceres, SPAIN. 2Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra, Pamplona, SPAIN. 3Department of Neurology, Clínica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, SPAIN. 4Department of Pharmacology, University of Extremadura, Cáceres, SPAIN. 5CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, SPAIN. 6Service of Neurology, Hospital Universitario Doce de Octubre, Madrid, SPAIN. 7Department of Medicine, University Complutense, Madrid, SPAIN. 8Department of Neurology, Hospital La Mancha-Centro, Alcázar de San Juan, Ciudad Real, SPAIN. 9Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Facultad de Ciencias, Universidad Autónoma, Cantoblanco, Madrid 28049, SPAIN. 10Section of Neurology, Hospital Universitario del Sureste, Arganda del Rey, Madrid, SPAIN. 11Department of Medicine-Neurology, Hospital “Príncipe de Asturias”, Universidad de Alcalá, Alcalá de Henares, Madrid, SPAIN.
References

1. Giordano M, D’Alfonso S, Morgignano-Richard P: Genetics of multiple sclerosis: linkage and association studies. Am J Pharmacogenomics 2002, 2:37–58.
2. Dharmaraj DA, Ebers GC, Sadovnick AD: Genetics of multiple sclerosis. Lancet Neurol 2004, 3:104–110.
3. Mandelbaum SV, Deluca GC, Degenhardt A, Ebers GC: The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008, 201:202–189.
4. Pugliatti M, Harfe HB, Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
5. Pugliatti M, Harbo HF, Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
6. Baranzini SE: Featured in AAIC: June 2010. Pugliatti M, Harbo HF, Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
7. Pugliatti M, Harbo HF, Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
8. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Domeniconi M, Filbin MT: Recent advances in genetics and genome-wide association studies in multiple sclerosis: lessons and future prospects. Brief Funct Genomics 2011, 10:61–70.
9. Pugliatti M, Harbo HF, Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
10. Baranzini SE: Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011, 21:317–324.
11. Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
12. Baranzini SE: Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011, 21:317–324.
13. Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
14. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
15. Baranzini SE: Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011, 21:317–324.
16. Holmoy T, Kampmann MT, Myhr KM, Riise T, Wolfson C: Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008, 188:34–40.
17. Baranzini SE: Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011, 21:317–324.
18. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
19. Baranzini SE: Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011, 21:317–324.
20. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
21. Baranzini SE: Revealing the genetic basis of multiple sclerosis: are we there yet? Curr Opin Genet Dev 2011, 21:317–324.
22. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
23. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
24. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
25. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
26. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
27. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
28. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
29. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
30. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
31. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
32. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
33. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
34. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data.Clin Chem 2008, 54:1390–1394.
35. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
36. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
37. Lee X, Shao Z, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Miller RH, Chan JR, Mi S: Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008, 54:1390–1394.
containing Nogo receptor-interacting protein-1 (LINGO1) in two independent Chinese Parkinson’s disease populations. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:99–103.

43. Guo Y, Jankovic J, Song Z, Yang H, Zheng W, Le W, Tang X, Deng X, Yang Y, Deng S, et al: LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett 2011, 487:174–178.

44. Zuo X, Jang H, Guo JF, Yu RH, Sun QY, Hu L, Wang L, Yao LY, Shen L, Fan Q, et al: Screening for two SNPs of LINGO1 gene in patients with essential tremor or sporadic Parkinson’s disease in Chinese population. Neurosci Lett 2010, 481:69–72.

45. Klebe S, Thier S, Lorenz D, Nothnagel M, Schreiber S, Klein C, Hagenah J, Kasten M, Berg D, Srulijes K, et al: LINGO1 is not associated with Parkinson’s disease in German patients. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:1173–1178.

46. Clark LN, Park N, Kisselev S, Rios E, Lee JH, Louis ED: Replication of the LINGO1 gene association with essential tremor in a North American population. Eur J Hum Genet 2010, 18:838–843.

47. Thier S, Lorenz D, Nothnagel M, Stevanin G, Durr A, Schreiber S, Kuhlenbaumer G, Deuschl G, Klebe S: LINGO1 polymorphisms are associated with essential tremor in Europeans. Mov Disord 2010, 25:717–723.

48. Bialecka M, Kurzawski M, Tan EK, Drozdzik M: Analysis of LINGO1 (rs9652490) polymorphism in sporadic Parkinson’s disease in a Polish population, and a meta-analysis. Neurosci Lett 2010, 472:53–55.

49. Haubenberger D, Hotzy C, Pök PAR T, Katsenschlager R, Brucke T, Zimpich F, Auff E, Zimpich A: Role of LINGO1 polymorphisms in Parkinson’s disease. Mov Disord 2009, 24:2404–2407.

50. Tan EK, Teo YY, Prakash K, Li R, Lim HQ, Angeles D, Tan LC, Au WL, Yih Y, Zhao Y: LINGO1 variant increases risk of familial essential tremor. Neurology 2009, 73:1161–1162.

doi:10.1186/1471-2377-13-34

Cite this article as: García-Martín et al.: LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. BMC Neurology 2013 13:34.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit